EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparative analysis of the information reported on labels of medicinal products containing new active substances between Europe and the USA.

Giuseppe Marano, Arianna Annunziata, Maria Cutillo, Roberto Da Cas, Francesca Menniti-Ippolito, Ilaria Ippoliti

Annali dell Istituto Superiore di Sanità · 17.06.2026 · 62 (2) · 115-120

DOI: 10.4415/ann_26_02_03 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Annali dell Istituto Superiore di Sanità, erschienen am 17.06.2026. Verfasst von Giuseppe Marano und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centro Nazionale per la Ricerca e la Valutazione Preclinica e Clinica dei Farmaci, Istituto Superiore di Sanità, Rome, Italy. Hauptthemen laut MEDLINE: Drug Labeling.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Although notable efforts have been made to harmonise regulatory processes for the approval of new therapeutic drugs by the competent authorities, some discrepancies concerning risk-benefit assessments and regulatory actions remain.

Methods

This analysis compared the approaches of the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) in the approval of new active substances and identified potential clinical implications associated with these differences in “Indication”, “Contraindications” and “Posology and administration of drugs” sections of drug summary of products characteristics (SmPC).

Results

The overall analysis showed major differences in 63.9% for the indications, in 75% for contraindications and in 13.9% for posology. Considering the more represented therapeutic areas (cancer and haematology/haemostaseology drugs), the percentage of major differences for the indications was 70% in cancer area and 50% in haematology/ haemostaseology area. For contraindications major differences were observed in 90% of cancer drugs, and 60% in haematology/haemostaseology drugs.

Discussion

Our findings highlight the need of further efforts on harmonizing decision making driven by scientific data between regulatory authorities in the interest of patients in a public health perspective.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug LabelingUnited StatesEuropeHumansDrug ApprovalUnited States Food and Drug AdministrationBulk Drugs

Substanzen

Bulk Drugs

Autor:innen und Institutionen

  • Centro Nazionale per la Ricerca e la Valutazione Preclinica e Clinica dei Farmaci, Istituto Superiore di Sanità, Rome, Italy.

Zitieren

APA

Marano, G., Annunziata, A., Cutillo, M., Da Cas, R., Menniti-Ippolito, F., & Ippoliti, I. (2026). Comparative analysis of the information reported on labels of medicinal products containing new active substances between Europe and the USA. Annali dell Istituto Superiore di Sanità, 62(2), 115-120. https://doi.org/10.4415/ann_26_02_03

Vancouver

Marano G, Annunziata A, Cutillo M, Da Cas R, Menniti-Ippolito F, Ippoliti I. Comparative analysis of the information reported on labels of medicinal products containing new active substances between Europe and the USA. Annali dell Istituto Superiore di Sanità. 2026;62(2):115-120. doi:10.4415/ann_26_02_03

BibTeX
@article{Marano2026,
  author = {Marano, Giuseppe and Annunziata, Arianna and Cutillo, Maria and Da Cas, Roberto and Menniti-Ippolito, Francesca and Ippoliti, Ilaria},
  title = {Comparative analysis of the information reported on labels of medicinal products containing new active substances between Europe and the USA},
  journal = {Annali dell Istituto Superiore di Sanità},
  year = {2026},
  volume = {62},
  number = {2},
  pages = {115--120},
  doi = {10.4415/ann_26_02_03}
}
Kostenlos starten →